Abnormal cervical cytology is associated with preterm delivery: A population based study.


Journal

Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343

Informations de publication

Date de publication:
06 2019
Historique:
received: 21 06 2018
revised: 16 12 2018
accepted: 11 01 2019
pubmed: 23 1 2019
medline: 28 1 2020
entrez: 23 1 2019
Statut: ppublish

Résumé

Increasing evidence suggests that cervical intraepithelial neoplasia, with or without subsequent treatment, is associated with preterm delivery. We aimed to explore the association between abnormal cervical cytology of different severity and the subsequent obstetric outcomes such as preterm delivery. The historical register-based cohort study comprised 19 822 women in the Western Region of Sweden who had at least one abnormal cervical cytology from 1978 to 2012 before the age of 45 and a subsequent singleton delivery. The reference group comprised 39 644 women with normal cervical cytology and a subsequent singleton delivery, matched by age and parity. Data were retrieved from the Swedish National Cervical Screening Registry, linked to the Swedish Medical Birth Register and Statistic Sweden. The study outcomes were spontaneous preterm delivery before 37 and 34 weeks, low birthweight (≤2500 g), small-for-gestational-age, preterm premature rupture of membranes and neonatal mortality. Multivariable log binominal regression analyses were applied. Preterm delivery before 37 weeks was more common among women with abnormal cervical cytology compared with reference group: 6% vs 4.5%; adjusted relative risk 1.30 (95% confidence interval 1.21-1.39). High vs low-grade abnormal cervical cytology implied a higher risk: 7% vs 5.8% (P < 0.001). Early preterm delivery before 34 weeks, preterm premature rupture of membranes and low birthweight, but not small-for-gestational-age and neonatal mortality, were significantly more common in women with abnormal cervical cytology compared with the reference group. Abnormal cervical cytology may imply an increased risk of preterm delivery. Further studies are needed to investigate whether that risk is related to treatment.

Identifiants

pubmed: 30667051
doi: 10.1111/aogs.13543
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

777-786

Subventions

Organisme : Assar Gabrielsson's Foundation for Cancer-related Clinical Research
Pays : International
Organisme : Hjalmar Svensson's Research Foundation
Pays : International
Organisme : The Gothenburg Medical Society
Pays : International
Organisme : Research Foundation of Western Sweden and Swedish Association of Local Authorities and Regions
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Nordic Federation of Societies of Obstetrics and Gynecology.

Auteurs

Tagrid Jar-Allah (T)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Cecilia Kärrberg (C)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Johanna Wiik (J)

Department of Gynecology and Obstetrics, Østfold Hospital Trust, Kalnes, Norway.
Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Verena Sengpiel (V)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Björn Strander (B)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Swedish National Cervical Screening Registry, Regional Cancer Center, West Sweden, Gothenburg, Sweden.

Erik Holmberg (E)

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Annika Strandell (A)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH